vTv Therapeutics (VTVT) Income from Continuing Operations (2014 - 2026)
vTv Therapeutics (VTVT) posted Income from Continuing Operations of 24134000.0 for Q1 2026, up 438.11% sequentially from 7138000.0 in Q4 2025, and up 488.19% YoY from 4103070.39 in Q1 2025.
vTv Therapeutics (VTVT) Income from Continuing Operations (2014 - 2026) Analysis & Trends
vTv Therapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 24134000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 488.19% year-over-year to 24134000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 729000.0 (up 96.82% YoY) and the FY2025 annual result came in at 31080000.0, down 36.89% from the prior year.
- Income from Continuing Operations climbed to 24134000.0 in Q1 2026 per VTVT's latest filing, from 7138000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 24134000.0 in Q1 2026 and troughed at 10345000.0 in Q3 2025.
- A 5-year average of 4746470.59 and a median of 6090000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations sank 386.44% in 2022, then soared 488.19% in 2026.
- Over 5 years, Income from Continuing Operations stood at 6090000.0 in 2022, then grew by 27.08% to 4441000.0 in 2023, then advanced by 0.09% to 4437000.0 in 2024, then slumped by 60.87% to 7138000.0 in 2025, then soared by 438.11% to 24134000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 24134000.0, 7138000.0, and 10345000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | vTv Therapeutics | 373.77 Mn | 373.77 Mn | - | -13.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.05 Mn |
| Mar 31, 2026 | 24.13 Mn |
| Dec 31, 2025 | -7.14 Mn |
| Sep 30, 2025 | -10.35 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | -6.22 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | -5.84 Mn |
| Jun 30, 2024 | -6.41 Mn |
| Mar 31, 2024 | -6.02 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Sep 30, 2023 | -8.54 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -5.77 Mn |
| Dec 31, 2022 | -6.09 Mn |
| Sep 30, 2022 | -5.47 Mn |
| Jun 30, 2022 | -4.09 Mn |
| Mar 31, 2022 | -9.42 Mn |
| Dec 31, 2021 | -9.48 Mn |
| Sep 30, 2021 | -1.47 Mn |